American Society of Hirudotherapy

Reduced axon sprouting after treatment that diminishes microglia accumulation at lesions in the leech CNS.

Research article published in The Journal of comparative neurology (2007)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genomics & ProteomicsSalivary PharmacologyNgu et al. · The Journal of comparative neurology, 2007

Abstract

The role of mammalian microglia in central nervous system (CNS) repair is controversial. Microglia accumulate at lesions where they act as immune cells and phagocytize debris, and they may secrete neurotrophins, but they also produce molecules that can be cytotoxic, like nitric oxide (NO). To determine the importance of microglial accumulation at lesions on growth of severed CNS axons in the leech (Hirudo medicinalis), in which axon and synapse regeneration are notably successful even when isolated in tissue culture medium, microglial migration to lesions was reduced. Pressure (P) sensory neurons were injected with biocytin to reveal the extent of their sprouting 24 hours after lesioning. To reduce microglia accumulation at lesions, cords were treated for 3.5 hours with 3 mM ATP or 2 mM N(omega)-nitro-L-arginine methyl ester (L-NAME) or 50 microM Reactive blue-2 (RB2) beginning 30 minutes before injury. Lesioned controls were either not treated with drug or treated 3 hours later with one of the drugs, after the migration and subsequent accumulation of most microglia had occurred, but before the onset of axon sprouting, for a total of seven separate conditions. There was a significant reduction in total sprout lengths compared with controls when microglial accumulation was reduced. The results suggest that microglial cells are necessary for the usual sprouting of injured axons.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, N.I.H., Extramural
Indexed MeSH termsAdenosine TriphosphateAnimalsAxonsCentral Nervous SystemLeechesMicrogliaNerve CrushNerve RegenerationNeurons, AfferentNitric OxideTime FactorsWound Healing

Summary

The role of mammalian microglia in central nervous system (CNS) repair is controversial. Microglia accumulate at lesions where they act as immune cells and phagocytize debris, and they may secrete neurotrophins, but they also produce molecules that can be cytotoxic, like nitric oxide (NO).

Why This Matters for Hirudotherapy

This study (Ngu et al., 2007, J. Comp. Neurol.) used the medicinal leech (Hirudo medicinalis) CNS as a model to test whether microglia are needed for injured-axon regrowth: after lesioning, pharmacologically reducing microglial accumulation (with ATP, L-NAME, or Reactive blue-2) produced a significant reduction in total sprout lengths of severed sensory neurons versus controls, suggesting microglia are necessary for the usual sprouting of injured axons. Its relevance to ASH is indirect but real — it draws on the same Hirudo medicinalis species central to hirudotherapy and reflects the leech's value as a regeneration model in neuroscience, part of the broader scientific interest in the organism, rather than evidence about leech therapy in patients. Honest caveat: this is preclinical invertebrate neurobiology about axon regeneration; it says nothing about the medicinal-leech salivary secretome, anticoagulation, or any clinical hirudotherapy outcome, and should not be cited as therapeutic evidence.

Citation

Reduced axon sprouting after treatment that diminishes microglia accumulation at lesions in the leech CNS.

Ngu et al. · The Journal of comparative neurology, 2007

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.